Who was studied, and how
Two numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 10 other studies
300people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
liraglutide
placebo
No clear effect on deaths1.1×
No clear effect on rehospitalizations for heart failure+30%
randomisedthe abstract, start to end
… in the placebo group; hazard ratio, 1.10 [95% CI, 0.57-2.14]; P = .78) or rehospitalizations for heart failure (63 [41%] vs 50 [34%], respectively; hazard ratio, 1.30 [95% CI, 0.89-1.88]; P = .17) …
← favours treatmentfavours comparator →
could be chanceDeathsliraglutide vs placebo
HR 1.100.57–2.14
Rehospitalizations for heart failureliraglutide vs placebo
HR 1.300.89–1.88
GLP-1 receptor agonistsAll-cause mortalityAdverse events & safety
GLP-1 receptor agonists × all-cause mortalityhelps?replicated
unlikelylikely
0.880.88 without it
GLP-1 receptor agonists × adverse events & safetyharms?mixed
unlikelylikely
0.020.02 without it
← favours treatmentfavours comparator →
1 / 6